Abstract
A major challenge today is the integration of Traditional Chinese Medicines (TCM), particularly herbal preparations, into the global pharmaceutical industry. This paper explains the approach used by a modern TCM Company, Marco Polo Technologies (MPT), working with partners and collaborators in the US, China, and Taiwan. MPT’s ultimate objective is to develop FDA approved therapeutics for the treatment of chronic diseases. The company’s strategy involves the early development of standardized TCM that can be marketed as nutritional supplements in both the US and Asia. The development of FDA therapeutics is based on combinatorial medicines that have a mixture of active compounds. MPT’s activities, including acquiring raw materials, product development, manufacturing, and clinical trials, involve a significant amount of work in China and Taiwan. MPT has now developed three products for skin infections, allergies, and arthritis. In order to gain approval for these products, MPT had to overcome numerous hurdles presented by the FDA and the Patent Office.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Springer Science+Business Media New York
About this chapter
Cite this chapter
Yuan, R. (2001). Marco Polo Technologies. In: Lin, Y. (eds) Drug Discovery and Traditional Chinese Medicine. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-1455-8_20
Download citation
DOI: https://doi.org/10.1007/978-1-4615-1455-8_20
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-5562-5
Online ISBN: 978-1-4615-1455-8
eBook Packages: Springer Book Archive